That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

The results also make MariTide the first obesity treatment with monthly or less frequent dosing to show effective weight loss in a phase 2 study, according to the company. Despite that assessment ...

The medication can be taken monthly by injection and resulted in an average weight loss of up to 20% over 52 weeks, according to data released by the company. Unlike other treatments, MariTide has ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

MariTide demonstrated robust weight loss at 52 weeks without a weight loss plateau, significant improvements in cardiometabolic parameters, and is the first obesity treatment with monthly or less ...

MariTide Phase 3 studies to begin in first half ... placed a hold on an early-stage trial of a different experimental weight-loss drug. The company's shares, which have gained more than 11% ...

It has a robust oncology franchise as well. MariTide, its weight-loss medication, may revolutionize the market. MariTide provides the ease of a once-monthly dose, which is a significant benefit in ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...